1 option
Clinical review report : (Bausch Health, Canada Inc.) : indication: an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia). Naltrexone hydrochloride and bupropion hydrochloride (Contrave) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Adulthood.
- Type 2 diabetes.
- Obesity.
- Physical Description:
- 1 online resource (121 pages) : illustrations
- Edition:
- Version: Final.
- Place of Publication:
- Canada : Canadian Agency for Drugs and Technologies in Health, 2020.
- Summary:
- The objective of the review is to perform a systematic review of the beneficial and harmful effects of naltrexone hydrochloride 8 mg and bupropion hydrochloride 90 mg (Contrave) extended-release tablets, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia).
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.